Transcarent
Transcarent is a healthcare technology company. Its AI-powered WayFinding™ platform offers scheduling, symptom checking, and personalized care guidance.
Secondary Market Price
How Transcarent Measures Up
To help you manage your Transcarent equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Transcarent's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Transcarent Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Transcarent's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Transcarent is a healthcare technology company founded in 2020 that develops software to help people access and manage their healthcare. The company’s primary offering is a platform called WayFinding™, which uses generative AI to provide users with information on behavioral health, pharmacy medication pricing, and prescription transfers, as well as access to clinically integrated care guidance. Headquartered in San Francisco, California, the company was established by a team that includes CEO Glen Tullman and Co-Founder Krishnan Sridharan. Since its founding, Transcarent has grown to between 1,001 and 5,000 employees.
The company is currently focused on expanding its platform's AI capabilities. At CES 2026, Transcarent announced WayFinding™ 2.0, an update that introduces agentic AI features designed to take proactive steps for the user. These new functions include AI-powered voice scheduling for appointments, a conversational symptom-checking tool, a "memory engine" for persistent reminders, and personalized preventive health recommendations. This development, which follows a Series D funding round of $481 million on May 8, 2025, marks a strategic shift from providing chat-based answers to enabling the platform to perform direct actions on behalf of the user.
- General Catalyst
- 7wireVentures
- Kinnevik
- Human Capital
- Ally Bridge Group
- Geodesic Capital
- Memorial Hermann Health System
- Threshold Ventures
- Merck Global Health Innovation Fund
- Alta Partners
- Leaps by Bayer
- Kleiner Perkins
- GreatPoint Ventures
- Northwell Health
- Intermountain Healthcare
- Rush University Medical Center
- Co-Founder, Glen Tullman
- Co-Founder, Hemant Taneja
- Co-Founder, Lee Shapiro
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Transcarent worth joining?
Joining any pre-IPO company like Transcarent requires careful consideration of its growth prospects and your potential equity compensation. Tools like Prospect can help you model the future value of your equity to make a more informed decision.
What should I do with my Transcarent stock?
Deciding what to do with your pre-IPO stock involves complex tax and financial planning, including when to exercise options and when to sell. Prospect offers personalized strategies and scenario modeling to help you maximize the value of your equity.
Can you sell Transcarent stock?
As Transcarent is a private company, selling stock is typically possible only during specific liquidity events like tender offers or on secondary markets. Platforms like Prospect can help you navigate these opportunities and determine the most tax-optimal shares to sell.
How can I find the value of my Transcarent stock?
The value of private stock is typically based on the company's 409A valuation, but this may not reflect its true market value. Prospect provides predictive models and access to secondary market data to help you better forecast your equity's potential worth.
What is Transcarent's equity worth?
As a private company, Transcarent's exact equity valuation is not public information and changes with new funding rounds and business performance. You can use tools from Prospect to model different valuation scenarios and project the future value of your specific holdings.
What is Transcarent's stock ticker symbol?
Since Transcarent is a private company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company completes an Initial Public Offering (IPO).
Can I buy or sell Transcarent stock?
Buying shares in a private company like Transcarent is typically restricted to accredited investors and employees, while selling is limited to company-approved tender offers or secondary market sales. Prospect offers tools to help employees navigate sales opportunities and optimize their financial outcomes.
What is the criteria to buy or invest in Transcarent stock?
Investing in a private company like Transcarent is generally limited to employees as part of their compensation or to accredited investors during formal fundraising rounds. For employees who hold equity, resources like Prospect can provide guidance on managing and maximizing its value.
